682. Comparison of Population-Specific Cystic Fibrosis Antibiograms versus Hospital-Wide Antibiograms for Two Cystic Fibrosis Centers
Session: Poster Abstract Session: They've Been Here a Billion Years! Pediatric Bacterial and Viral Infections
Thursday, October 27, 2016
Room: Poster Hall
Background: Patients with cystic fibrosis (CF) experience significant morbidities associated with chronic infection and are often colonized and infected with highly drug-resistant organisms. However, since traditional hospital antibiograms lack information on individual factors (such as infection site and patient risk factors), they may falsely represent susceptibilities in a CF population and are not commonly used to guide empiric antimicrobial choice. The purpose of this study was to develop customized CF antibiograms and compare each CF antibiogram with those of the larger hospitals where these CF Centers reside.

Methods: This retrospective, observational cohort study included susceptibility data from all CF respiratory cultures collected from patients with a confirmed CF diagnosis over a 6-year period (January 2010- December 2015) at two children’s hospital sites (located 35 miles apart) and their parent institutions. CF antibiograms were developed for each site and compared to their respective hospital-wide antibiograms.

Results: A total of 1220 cultures were collected from 138 patients with CF. There was a significant difference between the two CF Centers in the mean patient age (Site 1: 26.8 ± 12.7 vs Site 2: 11.8 ± 7.3; p <0.0001). Pseudomonas aeruginosa, MSSA, and MRSA were the most prevalent organisms identified. Significant differences in MRSA were observed in the CF vs hospital antibiograms at each of the two sites (Site 1: 23% vs 36%, p <0.001; Site 2: 16.5% vs 40%, p < 0.0001). Pseudomonas aeruginosa exhibited significantly increased resistance for all antimicrobials at the 1st CF Center site compared to its parent institution (p <0.0001), however, this was not observed at the 2nd CF Center site.

Conclusion: Due to differences in susceptibilities between CF and hospital-wide antibiograms, customized CF antibiograms are warranted to guide optimal empiric antimicrobial therapy and promote antimicrobial stewardship.

Victoria Konold, MD, Department of Pediatrics, Advocate Lutheran General Hospital, Park Ridge, IL, Kimberly Watts, MD, MS, Advocate Medical Group/Department of Pediatrics, Advocate Lutheran General Hospital, Park Ridge, IL, Denise Angst, PhD, RN, Medical Education/Research, Advocate Christ Medical Center, Hope Children's Hospital, Oak Lawn, IL and Sarah M. Wieczorkiewicz, Pharm.D., BCPS (AQ-ID), Pharmacy, Advocate Lutheran General Hospital, Park Ridge, IL

Disclosures:

V. Konold, None

K. Watts, None

D. Angst, None

S. M. Wieczorkiewicz, None

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.